Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Allovir, Inc. | Chief Commercial Officer | Common Stock | 147K | $98.6K | $0.67 | Jul 3, 2023 | Direct |
Adaptimmune Therapeutics PLC | Chief Commercial Officer | American Depositary Shares representing Ordinary Shares | 38.3K | $35.6K | $0.93 | Jun 18, 2024 | Direct |
Adaptimmune Therapeutics PLC | Chief Commercial Officer | Option to purchase Ordinary Shares | 1.13M | Mar 18, 2024 | Direct | ||
Allovir, Inc. | Chief Commercial Officer | Stock Option (Right to Buy) | 273K | Jul 3, 2023 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
ADAP | Adaptimmune Therapeutics PLC | Jun 18, 2024 | 1 | -$22.8K | 4 | Jun 18, 2024 | Chief Commercial Officer |
ADAP | Adaptimmune Therapeutics PLC | Mar 18, 2024 | 2 | $0 | 4 | Mar 18, 2024 | Chief Commercial Officer |
ALVR | Allovir, Inc. | Jul 3, 2023 | 2 | $0 | 4 | Jul 5, 2023 | Chief Commercial Officer |
ALVR | Allovir, Inc. | Jun 12, 2023 | 0 | $0 | 3 | Jun 21, 2023 | Chief Commercial Officer |
ADAP | Adaptimmune Therapeutics PLC | Jan 31, 2023 | 1 | -$22.2K | 4 | Jan 31, 2023 | Chief Commercial Officer |
ADAP | Adaptimmune Therapeutics PLC | Jan 17, 2023 | 3 | $0 | 4 | Jan 17, 2023 | Chief Commercial Officer |
ADAP | Adaptimmune Therapeutics PLC | Aug 1, 2022 | 1 | -$37.3K | 4 | Aug 1, 2022 | Chief Commercial Officer |
ADAP | Adaptimmune Therapeutics PLC | Jan 31, 2022 | 3 | $0 | 4 | Jan 31, 2022 | Chief Commercial Officer |
ADAP | Adaptimmune Therapeutics PLC | Jan 31, 2022 | 0 | $0 | 3 | Jan 31, 2022 | Chief Commercial Officer |